New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study
Tan, Li T.
Sagoo, Gurdeep S.
Hulbert-Williams, Nicholas J.
Pharoah, Paul D. P.
AffiliationUniversity of Cambridge; Cambridge University Hospitals NHS; PHG Foundation; Peterborough and Stamford Hospitals NHS Foundation; The Ipswich Hospital NHS Trust; Hinchingbrooke Health; Norfolk & Norwich University Hospitals NHS Foundation Trust; The Queen Elizabeth Hospital King’s Lynn NHS Foundation Trust; University of Cambridge Department of Oncology and NIHR Cambridge Biomedical Research Centre; University of Chester; Cancer Research UK Cambridge Institute
MetadataShow full item record
AbstractBackground: Over recent years genetic testing for germline mutations in BRCA1/BRCA2 has become more readily available because of technological advances and reducing costs. The Genetic Testing in Epithelial Ovarian Cancer (GTEOC) Study explored the feasibility and acceptability of offering genetic testing to all women recently diagnosed with epithelial ovarian cancer (EOC). Methods: From 1st July 2013 to 30th June 2015 women newly diagnosed with EOC were recruited through six sites in East Anglia, UK. Eligibility was irrespective of patient age and family history of cancer. The psychosocial arm of the study utilised self-report, psychometrically validated questionnaires (Depression Anxiety and Stress Scale, DASS-21; Impact of Event Scale, IES) and cost analysis was performed. Results: 232 women were recruited and 18 mutations were detected (12 in BRCA1, 6 in BRCA2) giving a mutation yield of 8% which increases to 12% in unselected women <70 years (17/146) and 1% in unselected women >70 years (1/86). IES and DASS-21 scores in response to genetic testing were significantly lower than equivalent scores in response to cancer diagnosis (p<.001). Correlation tests indicated that whilst older age is a protective factor against any traumatic impacts of genetic testing, no significant correlation exists between age and distress outcomes. Conclusion: The mutation yield in unselected women diagnosed with EOC from a heterogeneous population with no founder mutations was 8% in all ages and 12% in women under 70. Unselected genetic testing in women with EOC was acceptable to patients and is potentially less resource-intensive than current standard practice.
CitationPlaskocinska, I., et. al. (2016). New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer – results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) Study. Journal of Medical Genetics, 53(10), 655-61. DOI: 10.1136/ jmedgenet-2016-103902
JournalJournal of Medical Genetics
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/4.0/